CoChat

Clinical Pharmacokinetics and Pharmacodynamics of Naloxone

Open access
Saari, Teijo I., Strang, John, Dale, Ola · 2024 · Clinical Pharmacokinetics

The DOI matches its Crossref record; 154 of the 154 references it cites were found in a registry or an index.

Abstract

Naloxone is a World Health Organization (WHO)-listed essential medicine and is the first choice for treating the respiratory depression of opioids, also by lay-people witnessing an opioid overdose. Naloxone acts by competitive displacement of opioid agonists at the μ-opioid receptor (MOR). Its effect depends on pharmacological characteristics of the opioid agonist, such as dissociation rate from the MOR receptor and constitution of the victim. Aim of treatment is a balancing act between restoration of respiration (not consciousness) and avoidance of withdrawal, achieved by titration to response after initial doses of 0.4–2 mg. Naloxone is rapidly eliminated [half-life ( t 1/2 ) 60–120 min] due to high clearance. Metabolites are inactive. Major routes for administration are intravenous, intramuscular, and intranasal, the latter primarily for take-home naloxone. Nasal bioavailability is about 50%. Nasal uptake [mean time to maximum concentration ( T max ) 15–30 min] is likely slower than intramuscular, as reversal of respiration lag behind intramuscular naloxone in overdose victims. The intraindividual, interindividual and between-study variability in pharmacokinetics in volunteers are large. Variability in the target population is unknown. The duration of action of 1 mg intravenous (IV) is 2 h, possibly longer by intramuscular and intranasal administration. Initial parenteral doses of 0.4–0.8 mg are usually sufficient to restore breathing after heroin overdose. Fentanyl overdoses likely require higher doses of naloxone. Controlled clinical trials are feasible in opioid overdose but are absent in cohorts with synthetic opioids. Modeling studies provide valuable insight in pharmacotherapy but cannot replace clinical trials. Laypeople should always have access to at least two dose kits for their interim intervention.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40262-024-01355-6

Cites

154 of 154 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The chemical structure of the µ-opioid receptor antagonist naloxone. An asymmetric carbon atom creates a chiral structure, resulting optical isomers of which only the levo-isomer is biologically active in the µ-opioid receptor
Fig. 1 The chemical structure of the µ-opioid receptor antagonist naloxone. An asymmetric carbon atom creates a chiral structure, resulting optical isomers of which only the levo-isomer is biologically active in the µ-opioid receptorCC BY-NC · PubMed Central
Fig. 2 Time course (left: 0–240 min, right: 0–60 min) of plasma concentrations of intravenous and intramuscular naloxone (0.4 mg) and concentrated intranasal formulations of 1, 2, and 4 mg naloxone. Note the initial closeness of serum concentrations of the regulatory golden standard 0.4 mg intramuscular dose and the 2 mg intranasal dose. Note also that plasma concentrations after 2 mg intranasal naloxone surpass that of 0.4 mg intramuscular naloxone after 6 min and stay above that of intramuscular for the remaining 120 min. Also, note the dramatic overshoot by the 4 mg dose compared with the 0.4 mg intramuscular dose. Redrawn from McDonald et al. [83] with permission
Fig. 2 Time course (left: 0–240 min, right: 0–60 min) of plasma concentrations of intravenous and intramuscular naloxone (0.4 mg) and concentrated intranasal formulations of 1, 2, and 4 mg naloxone. Note the initial closeness of serum concentrations of the regulatory golden standard 0.4 mg intramuscular dose and the 2 mg intranasal dose. Note also that plasma concentrations after 2 mg intranasal naloxone surpass that of 0.4 mg intramuscular naloxone after 6 min and stay above that of intramuscular for the remaining 120 min. Also, note the dramatic overshoot by the 4 mg dose compared with the 0.4 mg intramuscular dose. Redrawn from McDonald et al. [83] with permissionCC BY-NC · PubMed Central
Fig. 3 Dose–concentration linearity for maximum serum concentration (Tmax) and area under the curve (AUC) after nasal spraying of 0.8–2.0 mg of concentrated nasal naloxone formulations in healthy volunteers (compiled from two different studies [48, 62] with the same formulation). This linearity is the scientific basis for a two-dose administration by laypeople in take-home naloxone (THN)
Fig. 3 Dose–concentration linearity for maximum serum concentration (Tmax) and area under the curve (AUC) after nasal spraying of 0.8–2.0 mg of concentrated nasal naloxone formulations in healthy volunteers (compiled from two different studies [48, 62] with the same formulation). This linearity is the scientific basis for a two-dose administration by laypeople in take-home naloxone (THN)CC BY-NC · PubMed Central
Fig. 4 Inter- and intraindividual variability of the absolute bioavailability of intranasal naloxone [AUC(IN)/AUC(IV) × DOSE(IV)/DOSE(IN)] based on AUC0−inf in 22 healthy volunteers. Not only does the absolute nasal bioavailability vary from about 20% to almost 100% between individuals but also is usually reproduced in an individual. Similar findings were observed for the relative intranasal to intramuscular bioavailability in the same subjects [19]
Fig. 4 Inter- and intraindividual variability of the absolute bioavailability of intranasal naloxone [AUC(IN)/AUC(IV) × DOSE(IV)/DOSE(IN)] based on AUC0−inf in 22 healthy volunteers. Not only does the absolute nasal bioavailability vary from about 20% to almost 100% between individuals but also is usually reproduced in an individual. Similar findings were observed for the relative intranasal to intramuscular bioavailability in the same subjects [19]CC BY-NC · PubMed Central
Fig. 5 Time course of pupil diameter in healthy volunteers exposed to remifentanil and naloxone [n = 12, mean (95% confidence interval)]. Remifentanil was started at t = −12 min and stopped at t = 90 min (orange, horizontal line). Miosis was rapidly reversed by a naloxone bolus of 1 mg intravenously given at t = 0. The blue broken line is the regression line [f(x) = − 0.0292x + 6.9924)] and is based on the period 19–89 min. It crosses the nadir baseline (black dotted line) at 118 min. The blood concentration of naloxone at this point was 0.5 ng/ml, which is the minimum effective concentration of naloxone in steady state. Redrawn from Tylleskar et al. [63] with permission
Fig. 5 Time course of pupil diameter in healthy volunteers exposed to remifentanil and naloxone [n = 12, mean (95% confidence interval)]. Remifentanil was started at t = −12 min and stopped at t = 90 min (orange, horizontal line). Miosis was rapidly reversed by a naloxone bolus of 1 mg intravenously given at t = 0. The blue broken line is the regression line [f(x) = − 0.0292x + 6.9924)] and is based on the period 19–89 min. It crosses the nadir baseline (black dotted line) at 118 min. The blood concentration of naloxone at this point was 0.5 ng/ml, which is the minimum effective concentration of naloxone in steady state. Redrawn from Tylleskar et al. [63] with permissionCC BY-NC · PubMed Central
Fig. 6 Hysteresis plot of pupil diameter and naloxone concentration during a remifentanil infusion with stable blood concentrations (see legend for Fig. 5). The red line represents arterial samples, and the blue line represent venous samples. The direction of time is illustrated by the arrow. This finding allows for the use of venous concentrations in PK/PD modeling. Redrawn from Tylleskar et al. [63] with permission
Fig. 6 Hysteresis plot of pupil diameter and naloxone concentration during a remifentanil infusion with stable blood concentrations (see legend for Fig. 5). The red line represents arterial samples, and the blue line represent venous samples. The direction of time is illustrated by the arrow. This finding allows for the use of venous concentrations in PK/PD modeling. Redrawn from Tylleskar et al. [63] with permissionCC BY-NC · PubMed Central
Fig. 7 Simulated time courses of mean naloxone concentrations (lines) and standard deviations as shaded areas: 0.8 mg intramuscular (dark gray), 0.4 mg intramuscular (light gray), and 1.4 mg intranasal (blue). Time of administration of injected naloxone is t = 0 min. A Intranasal 1.4 mg administered 10 min prior to injected naloxone (0.4 and 0.8 mg). B Simulation of the shortest time (2.25 min) beneficial to administer the intranasal spray, rather than wait for naloxone to be injected by medical personnel. C Simulation of 1.4 mg intranasal naloxone when intramuscular 0.4 mg naloxone is injected to a patient 10 min before the intranasal dose. Redrawn from Skulberg et al. [77]
Fig. 7 Simulated time courses of mean naloxone concentrations (lines) and standard deviations as shaded areas: 0.8 mg intramuscular (dark gray), 0.4 mg intramuscular (light gray), and 1.4 mg intranasal (blue). Time of administration of injected naloxone is t = 0 min. A Intranasal 1.4 mg administered 10 min prior to injected naloxone (0.4 and 0.8 mg). B Simulation of the shortest time (2.25 min) beneficial to administer the intranasal spray, rather than wait for naloxone to be injected by medical personnel. C Simulation of 1.4 mg intranasal naloxone when intramuscular 0.4 mg naloxone is injected to a patient 10 min before the intranasal dose. Redrawn from Skulberg et al. [77]CC BY-NC · PubMed Central
Fig. 8 Simulated concentration–time profiles of plasma naloxone after various common clinical dosing schemes in opioid overdose. A pharmacokinetic model based on our own data and 1000 simulations were used (Anesthesiology, manuscript in review) [108]. Two intravenous (0.4 and 2 mg, shown in gray and black, respectively) and three intramuscular doses (0.4, 0.8, and 2.0 mg, shown in light blue, yellow and blue, respectively) were simulated using the final pharmacokinetic model. The lower dotted line suggests the duration of action, represented by an experimentally determined minimum effective concentration of 0.5 ng/ml [76] and the upper dotted line suggests an increased risk of withdrawal, represented by the Cmax (3.2 ng/ml) and 0.8 mg intramuscular dose [18, 109]
Fig. 8 Simulated concentration–time profiles of plasma naloxone after various common clinical dosing schemes in opioid overdose. A pharmacokinetic model based on our own data and 1000 simulations were used (Anesthesiology, manuscript in review) [108]. Two intravenous (0.4 and 2 mg, shown in gray and black, respectively) and three intramuscular doses (0.4, 0.8, and 2.0 mg, shown in light blue, yellow and blue, respectively) were simulated using the final pharmacokinetic model. The lower dotted line suggests the duration of action, represented by an experimentally determined minimum effective concentration of 0.5 ng/ml [76] and the upper dotted line suggests an increased risk of withdrawal, represented by the Cmax (3.2 ng/ml) and 0.8 mg intramuscular dose [18, 109]CC BY-NC · PubMed Central
Fig. 9 Simulated plasma concentration profiles after single bolus doses (0.9, 1.4, 2.0, or 4.0 mg) of intranasal naloxone, alone or with remifentanil dosing (A and B, respectively) using a pharmacokinetic model based on our own data (Anesthesiology, manuscript in review) [108]. Plasma concentration–time course of the regulatory golden standard, an intramuscular 0.4 mg bolus dose, is shown in blue
Fig. 9 Simulated plasma concentration profiles after single bolus doses (0.9, 1.4, 2.0, or 4.0 mg) of intranasal naloxone, alone or with remifentanil dosing (A and B, respectively) using a pharmacokinetic model based on our own data (Anesthesiology, manuscript in review) [108]. Plasma concentration–time course of the regulatory golden standard, an intramuscular 0.4 mg bolus dose, is shown in blueCC BY-NC · PubMed Central
Fig. 10 A randomized, double-blinded comparison of naloxone given intramuscularly (0.8 mg, blue) or intranasally (1.4 mg, brown) by the ambulance service in opioid overdose (n = 201) Shaded areas represent 95% confidence interval. Kaplan–Meier plot showing the probability of not having reached satisfactory respiration (10 breaths/min). Curves are similar until 3 min, and the restoring of respiration is 2.3 min slower after the intranasal dose at 10 min. In real life, this difference is probably smaller, as intranasal administration is likely faster to complete than intramuscular. These intoxications were also more serious than those in an unselected material in the same catchment area [110]. Redrawn from Skulberg et al. [73]
Fig. 10 A randomized, double-blinded comparison of naloxone given intramuscularly (0.8 mg, blue) or intranasally (1.4 mg, brown) by the ambulance service in opioid overdose (n = 201) Shaded areas represent 95% confidence interval. Kaplan–Meier plot showing the probability of not having reached satisfactory respiration (10 breaths/min). Curves are similar until 3 min, and the restoring of respiration is 2.3 min slower after the intranasal dose at 10 min. In real life, this difference is probably smaller, as intranasal administration is likely faster to complete than intramuscular. These intoxications were also more serious than those in an unselected material in the same catchment area [110]. Redrawn from Skulberg et al. [73]CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 6

  1. Garfield E. The 1982 John Scott Award goes to Jack Fishman and Harold Blumberg for synthesis and investigations on naloxone. Essay Inf Sci. 1983;6:121–30.
  2. Blumberg H, Dayton HB, George M, Rapaport DN. N-allylnoroxynorphone; a potent narcotic antagonist. Fedn Proc Fedn Am Soc. 1961;20:311.
  3. Naloxone. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Naloxone#section=3D-Conformer. Accessed Oct 26 2022.
  4. World Health Organization, Management of Substance Abuse Team. Community management of opioid overdose. Geneva: World Health Organization; 2014.
  5. Lemen PM, Garrett DP, Thompson E, Aho M, Vasquez C, Park JN. High-dose naloxone formulations are not as essential as we thought. medRxiv. 2023;6:63.
  6. World Health Organization. WHO guidelines approved by the guidelines. Review committee community management of opioid overdose. Geneva: World Health Organization; 2014.

Cited by

See all 93

Metadata

Authors
Saari, T. I., Strang, J., & Dale, O.
Affiliations
  • University of Turku (FI)
  • King's College London (GB)
  • Norwegian University of Science and Technology (NO)
Corresponding author
Dale, Ola
Venue
Clinical Pharmacokinetics
Published
2024-03-14
Volume
63
Issue
4
Pages
397-422
ISSN
  • 0312-5963 (ISSN-L)
  • 1179-1926
OpenAlex
W4392796714
Cited by
77
References
154
Citations by year
2026: 41 · 2025: 29 · 2024: 7
FWCI
6.81
Type
journal article
Language
en
Open access
Licence
Locations
  • Clinical Pharmacokinetics (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • UTUPub (University of Turku) (submittedVersion, cc-by-nc)
Funders
NTNU Norwegian University of Science and Technology
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords
naloxone, opioid overdose, respiratory depression, mu-opioid receptor, pharmacokinetics, pharmacodynamics, intranasal administration, take-home naloxone, heroin overdose, fentanyl overdose, pharmacokinetic variability
MeSH terms
Administration, Intranasal, Analgesics, Opioid, Animals, Half-Life, Humans, Naloxone, Narcotic Antagonists, Drug Overdose

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.